Slamon DJ, Neven P, Chia S, Jerusalem G, et al. Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [An Ann Oncol 2021 Aug 16. pii: S0923-7534(21)02209.
PMID: 34412950